https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-10 09:18:172023-10-10 09:18:32Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2023/02/Pheon_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-10 09:18:172023-10-10 09:18:32Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2023/10/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-10 08:45:222024-01-11 14:15:56Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-09 16:11:092023-10-09 16:11:09Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting
https://www.optimumcomms.com/wp-content/uploads/2023/10/Template_Logo_300x180px-80x80Web_Logos-5.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-09 08:14:042023-10-09 09:22:49AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-05 08:55:232023-10-05 08:55:23Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/08/Rejuvenate_-Biomed_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-04 09:04:172023-10-04 09:04:17Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-03 21:30:462023-10-04 08:31:59IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/02/Amberimplants_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-03 08:14:092023-10-03 08:14:09Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-02 07:14:002023-10-02 07:14:57European Patent Office grants Futura Medical patent for MED3000 providing protection to 2040
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-29 09:23:322023-09-29 09:23:32Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-28 12:56:142023-09-28 12:56:48Women in Life Science Denmark (WiLD) launches its Female Leadership Mentoring Program to support career advancement for women in life science
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-28 08:56:572023-09-28 08:56:57Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-27 08:31:172023-09-27 09:13:484SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
https://www.optimumcomms.com/wp-content/uploads/2023/05/Acension_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-26 07:03:562023-09-26 07:03:56Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-25 08:48:482023-09-25 08:48:484SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 14:00:082023-09-22 11:55:49Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek PharmaceuticalsWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
